최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기대한소아신장학회지 = Journal of the Korean society of pediatric nephrology, v.14 no.1, 2010년, pp.1 - 9
하일수 (서울대학교 어린이병원 소아청소년과, 서울대학교 의과대학 의학연구원 신장연구소) , 최용 (인제대학교 해운대백병원 소아청소년과)
Slowing the progression of chronic kidney disease is much more important in children and adolescents with a relatively longer remaining life span. A practical way to assess the rate of progression of chronic kidney disease is to measure the change of GFR estimated by formulae. To slow the progressio...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
만성 콩팥병이 진행하여 말기 신질환이 됐을 때 어떤 치료가 최선인가? | 만성 콩팥병(chronic kidney disease)이 진행하여 말기 신질환(end-stage renal disease)이 되면 신 대체요법(renal replacement therapy)에 의존하게 되며 소아의 말기 신질환에서 최선의 치료는 콩팥 이식이다. 그러나 이식 후의 여러 가지 합병증으로 인해 이식 콩팥의 평균 생존 기간은 소아의 잔여 수명보다 훨씬 짧고, 재이식 콩팥의 평균 생존 기간은 일반적으로 더 짧다. | |
콩팥 이식이 가지는 한계점은 무엇인가? | 만성 콩팥병(chronic kidney disease)이 진행하여 말기 신질환(end-stage renal disease)이 되면 신 대체요법(renal replacement therapy)에 의존하게 되며 소아의 말기 신질환에서 최선의 치료는 콩팥 이식이다. 그러나 이식 후의 여러 가지 합병증으로 인해 이식 콩팥의 평균 생존 기간은 소아의 잔여 수명보다 훨씬 짧고, 재이식 콩팥의 평균 생존 기간은 일반적으로 더 짧다. 그러므로 만성 콩팥병의 진행을 억제하여 말기 신질환의 발생을 늦추는 것이 소아에서 매우 중요하다[1]. | |
만성 콩팥병과 연관된 조절이 가능한 인자에는 어떤 것이 있는가? | 조절이 가능한 인자들 중 요로 감염과 신독성 물질도 선행 인자로서 인과 관계를 인정할 수 있다. 이외의 조절 가능 인자들인 고혈압, 단백뇨, 빈혈, 저알부민혈증, 저칼슘혈증, 고인산혈증과 만성 콩팥병의 진행성과의 인과 관계를 확인하기 위해서는 이 인자들을 조절하는 전향적 무작위 대조 시험이 필요하다. |
Mitsnefes M, Ho PL, McEnery PT. Hypertension and progression of chronic renal insufficiency in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). J Am Soc Nephrol 2003;14:2618-22.
Litwin, M. Risk factors for renal failure in children with non-glomerular nephropathies. Pediatr Nephrol 2004;19:178-86.
Furth SL, Cole SR, Fadrowski JJ, Gerson A, Pierce CB, Chandra M, et al. The association of anemia and hypoalbuminemia with accelerated decline in GFR among adolescents with chronic kidney disease. Pediatr Nephrol 2007;22:265-71.
Soares CM, Diniz JS, Lima EM, Oliveira GR, Canhestro MR, Colosimo EA, et al. Predictive factors of progression to chronic kidney disease stage 5 in a predialysis interdisciplinary programme. Nephrol Dial Transplant 2009;24:848-55.
Wuhl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, et al. Strict blood pressure control and progression of renal failure in children. N Engl J Med 2009;361: 1639-50.
NKF. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(Suppl 1):S1-266.
Schwartz GJ, Haycock GB, Edelmann CM, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976;58:259-63.
Counahan R, Chantler C, Ghazali S, Kirkwood B, Rose F, Barratt TM. Estimation of glomerular filtration rate from plasma creatinine concentration in children. Arch Dis Child 1976;51:875-8.
Filler G, Lepage N. Should the Schwartz formula for estimation of GFR be replaced by cystatin C formula? Pediatr Nephrol 2003;18:981-5.
Bouvet Y, Bouissou F, Coulais Y, Seronie-Vivien S, Tafani M, Decramer S, et al. GFR is better estimated by considering both serum cystatin C and creatinine levels. Pediatr Nephrol 2006;21:1299-306.
Zappitelli M, Parvex P, Joseph L, Paradis G, Grey V, Lau S, et al. Derivation and validation of cystatin C-based prediction equations for GFR in children. Am J Kidney Dis 2006;48:221-30.
Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009;20:629-37.
Zappitelli M, Joseph L, Gupta IR, Bell L, Paradis G. Validation of child serum creatinine-based prediction equations for glomerular filtration rate. Pediatr Nephrol 2007;22:272-81.
Ardissino G, Testa S, Dacco V, Vigano S, Taioli E, Claris-Appiani A, et al. Proteinuria as a predictor of disease progression in children with hypodysplastic nephropathy. Data from the Ital Kid Project. Pediatr Nephrol 2004;19:172-7.
Lane PH. Puberty and chronic kidney disease. Adv Chronic Kidney Dis 2005;12: 372-7.
Kawaguchi H, Hattori M, Ito K. Somatic and renal effects of growth hormone in rats with chronic renal failure. Pediatr Nephrol 1997; 11:280-4.
Tonshoff B, Fine RN. Recombinant human growth hormone for children with renal failure. Adv Ren Replace Ther 1996;3:37-47.
Mehls O, Broyer M. Growth response to recombinant human growth hormone in short prepubertal children with chronic renal failure with or without dialysis. The European/Australian Study Group. Acta Paediatr Suppl 1994;399:81-7.
Soares CM, Diniz JS, Lima EM, Silva JM, Oliveira GR, Canhestro MR, et al. Clinical outcome of children with chronic kidney disease in a pre-dialysis interdisciplinary program. Pediatr Nephrol 2008;23:2039-46.
Hohenfellner K, Wingen AM, Nauroth O, Wuhl E, Mehls O, Schaefer F. Impact of ACE I/D gene polymorphism on congenital renal malformations. Pediatr Nephrol 2001;16: 356-61.
Lee-Chen GJ, Liu KP, Lai YC, Juang HS, Huang SY, Lin CY. Significance of the tissue kallikrein promoter and transforming growth factor-beta1 polymorphisms with renal progression in children with vesicoureteral reflux. Kidney Int 2004;65:1467-72.
Liu KP, Lin CY, Chen, HJ, Wei CF, Lee-Chen GJ. Renin-angiotensin system polymorphisms in Taiwanese primary vesicoureteral reflux. Pediatr Nephrol 2004;19: 594-601.
Gonzalez CC, Bitsori M, Tullus K. Progression of chronic renal failure in children with dysplastic kidneys. Pediatr Nephrol 2007; 22:1014-20.
Wong CS, Pierce CB, Cole SR, Warady BA, Mak RH, Benador NM, et al. Association of proteinuria with race, cause of chronic kidney disease, and glomerular filtration rate in the chronic kidney disease in children study. Clin J Am Soc Nephrol 2009;4:812-9.
Wuehl E, Mehls O, Schaefer F. ESCAPE Trial Group: Long-term dissociation of antiproteinuric and antihypertensive efficacy of ACE inhibition in children with chronic renal failure. COD.OC 16 [Abstract] Pediatr Nephrol 2006;21:1505.
Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004;66:753-60.
Schwarz S, Trivedi BK, Kalantar-Zadeh K, Kovesdy CP. Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol 2006;1:825-31.
Gooch K, Culleton BF, Manns BJ, Zhang J, Alfonso H, Tonelli M, et al. NSAID use and progression of chronic kidney disease. Am J Med 2007;120:270 e1-7.
Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. The effects of dietary protein restriction and bloodpressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994;330:877-84.
Chaturvedi S, Jones C. Protein restriction for children with chronic renal failure. Cochrane Database Syst Rev 2007;17:CD006863.
Ardissino G, Vigano S, Testa S, Dacco V, Paglialonga F, Leoni A, et al. No clear evidence of ACEi efficacy on the progression of chronic kidney disease in children with hypodysplastic nephropathy--report from the ItalKid Project database. Nephrol Dial Transplant 2007;22:2525-30.
The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349:1857-63.
Litwin M, Grenda R, Sladowska J, Antoniewicz J. Add-on therapy with angiotensin II receptor 1 blocker in children with chronic kidney disease already treated with angiotensin-converting enzyme inhibitors. Pediatr Nephrol 2006;21:1716-22.
Trachtman H, Christen E, Frank R, Rini J, Palestro C, Perelstein E, et al. Pilot Study of Mycophenolate Mofetil for Treatment of Kidney Disease due to Congenital Urinary Tract Disorders in Children. Am J Kidney Dis 2008;52:706-15.
Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59:260-9.
Perkins RM, Aboudara MC, Uy AL, Olson SW, Cushner HM, Yuan CM. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis 2009;53:606-16.
Iida S, Kohno K, Yoshimura J, Ueda S, Usui M, Miyazaki H, et al. Carbonic-adsorbent AST-120 reduces overload of indoxyl sulfate and the plasma level of TGF-beta1 in patients with chronic renal failure. Clin Exp Nephrol 2006;10:262-7.
Levin A. The advantage of a uniform terminology and staging system for chronic kidney disease (CKD). Nephrol Dial Transplant 2003;18:1446-51.
Shemin D, Bostom AG, Lambert C, Hill C, Kitsen J, Kliger AS. Residual renal function in a large cohort of peritoneal dialysis patients: change over time, impact on mortality and nutrition. Perit Dial Int 2000;20:439-44.
Guzzo I, Mancini E, Wafo SK, Rava L, Picca S. Residual renal function and nutrition in young patients on chronic hemodialysis. Pediatr Nephrol 2009;24:1391-7.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.